ReviewACS omega2026
Combining Gold and Selenium as Emerging Bioactive Compounds: From Synthesis to Therapeutic Potential.
Review in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Selenium: From Redox Signaling to Interactions with the Gut Microbiome.Biological trace element research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review outlines an overview of selenium-containing gold compounds, framed within the context of gold chemistry. It emphasizes key synthetic strategies and structural features of Au-Se complexes, encompassing both gold-(I) and gold-(III) species. Various classes of selenium ligands are discussed, including selenols, selenoureas, selenones, and selenium-NHCs, among other organoselenium ligands. Despite the relatively limited number of studies, these complexes exhibit diverse biological activities, including anticancer, antimicrobial, and anti-inflammatory effects. Mechanistic evidence suggests that these activities primarily arise from inhibition of thiol- and selenol-containing enzymes (e.g., thioredoxin reductase), disruption of redox homeostasis, or the induction of reactive oxygen species (ROS) formation. The synergistic interplay between gold and selenium centers is crucial for modulating these effects. This review highlights emerging trends in ligand optimization, providing a foundation for the rational design of next-generation selenium-based gold therapeutics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.